XNK Therapeutics appoints Michael Uhlin as Chief Scientific Officer

April 20, 2021 XNK Therapeutics AB (“XNK”) today announced the appointment of Professor Michael Uhlin as Chief Scientific Officer, effective August 1[st]. He will be a member of the company’s management team.Michael Uhlin, PhD, will be responsible for defining, implementing, and developing the company’s scientific strategy. He will lead a team involved in R&D and manufacturing with focus on platform development as well as improving production processes and executing operational research plans. Professor Uhlin received his master’s degree in medical research with a focus on biomedicine